Pyoderma Gangrenosum in Spain: Clinical Features, Therapeutic Management, and Outcomes in a 32‐Patient Case Series Authors: José‐Manuel Ramos‐Rincón, Jorge Esteban‐Jarabo, Marina Senent, Isabel Belinchón‐Romero Published: 2025 ABSTRACT ABSTRACTBackground and AimsPyoderma gangrenosum (PG) is a rare and challenging neutrophilic dermatosis characterized by painful, rapidly progressing necrotic ulcers. This study aimed to describe the demographic features, clinical presentations, associated systemic conditions, therapeutic approaches, and mortality risk factors in patients with PG. A sex‐based analysis was conducted to identify clinical differences.MethodsWe retrospectively reviewed the medical records of patients diagnosed with PG between 2000 and 2024 at Dr. Balmis General University Hospital (Spain).ResultsThirty‐two patients were included (24 women, 8 men), with a median age of 41 years (men: 61; women: 41; p < 0.001). The most frequent subtype was ulcerative PG (46.9%), usually presenting as a single lesion (IQR: 1–2), predominantly on the lower extremities (86.4%). Common associated conditions included inflammatory bowel disease (21.8%), rheumatoid arthritis (15.6%), and seronegative arthritis (9.4%). Treatments included topical therapies (48.4%), systemic drugs (74.4%), biologics (22.6%), and surgery (15.6%). The median time to disease control was 19 months (men: 16; women: 20; p = 0.041). Three patients, 9.4% (95% CI: 3.2%–24.2%) died during follow‐up. Significant associations were found for age (median: 73 vs. 40 years; p = 0.03) and sex (mortality in 37.5% of men vs. 0.0% of women; p = 0.01).ConclusionUlcerative PG was the most prevalent form, typically affecting the lower limbs. Inflammatory and autoimmune comorbidities were frequent. Most patients required systemic therapy, and disease control was often prolonged. The mortality was higher, and age was the main predictor.Keywords: comorbidities, inflammatory bowel disease, men, mortality, pyoderma gangrenosum, Spain, women Introduction Pyoderma gangrenosum (PG) is a complex and rare dermatological condition characterized by rapidly progressing, painful, necrotic ulcerations. It is classified as a noninfectious neutrophilic dermatosis, primarily affecting the skin but often associated with systemic inflammatory diseases [1]. PG is more frequently observed in adults between the ages of 30 and 50, with a higher prevalence in women [1]. The clinical presentation of PG is highly variable and may mimic other dermatological conditions, highlighting the importance of thorough differential diagnosis [2]. Although the exact pathogenesis remains unclear, PG is believed to involve dysregulation of both the innate and adaptive immune systems, suggesting an autoinflammatory mechanism [3]. With an estimated incidence of 3–10 cases per million inhabitants per year [1], PG is considered rare, which limits the feasibility of large observational cohorts or randomized controlled trials [4, 5, 6, 7]. Treatment is typically individualized, considering patient adherence and the presence of comorbid systemic diseases [6]. Most of the available evidence is derived from case reports and small case series due to the rarity and clinical heterogeneity of the disease [3, 4, 5, 6, 8, 9, 10]. Some studies have focused on PG subgroups associated with specific conditions such as inflammatory bowel disease [11, 12], rheumatoid arthritis [13], or peristomal PG [14], while others have addressed mortality and autopsy findings [15]. In Spain, the literature on PG largely consists of individual case reports [16] and small case series [17, 18], often describing patients with underlying conditions such as inflammatory bowel disease or lupus [19]. Notably, a recent nationwide analysis using hospital discharge data (1999–2021) reported a slight increase in PG‐related hospitalizations over the past two decades, along with insights into epidemiological patterns, clinical features, and risk factors for poor outcomes [20]. This study aims to describe the demographic characteristics, clinical presentations, associated systemic diseases, therapeutic strategies, and mortality risk factors among patients diagnosed with PG. A sex‐stratified analysis was performed to explore potential clinical differences. Methods Study Design, Setting, and Patients This was a retrospective study based on the review of medical records from the Dermatology Department of Dr. Balmis General University Hospital in Alicante, located on the Mediterranean coast of Spain. The study covered a 24‐year period, from 2000 to 2024. Hospital attendance records were screened using the International Classification of Diseases, 9th and 10th Revisions (ICD‐9 and ICD‐10) codes 686.01 and L88 (pyoderma gangrenosum). The diagnosis of PG was based on established clinical criteria, characterized by a rapidly progressive, painful ulcer with undermined borders, after excluding other causes such as infection, vascular disease, or malignancy. Diagnostic accuracy was further supported by the PARACELSUS score [21], with values ≥ 10 considered highly suggestive. Clinical records were independently reviewed by two researchers, who assessed clinical criteria and histopathological findings to confirm the diagnosis and rule out alternative conditions. Of the 43 patients initially identified, 4 were excluded due to histopathological findings inconsistent with PG (1 case of Sweet's syndrome, 2 cases of necrotizing pyodermatitis, and 1 of necrotizing vasculitis). Additionally, seven patients were excluded due to incomplete clinical, treatment, or follow‐up data. The patient selection process is illustrated in Figure 1. Patient selection process. Variables Collected The variables analyzed included: age, sex, PG subtype, lesion location and number, associated conditions (inflammatory bowel disease, neoplasms, rheumatoid arthritis, leukemia, stoma, monoclonal gammopathy of undetermined significance, Sweet's syndrome, and seronegative spondyloarthropathy), and unrelated comorbidities (obesity [body mass index ≥ 30], alcohol use, drug use, and smoking). Therapeutic modalities were classified as topical, systemic (oral or biological), or surgical. Laboratory data included glucose, creatinine, cholesterol, aspartate aminotransferase, hemoglobin, leukocyte count, and C‐reactive protein. Clinical outcomes included time to clinical control (in days) and all‐cause mortality. Statistical Analysis Categorical variables were expressed as frequencies (percentages), and continuous variables were reported as medians with interquartile ranges (IQR), due to non‐normal distributions confirmed by the Kolmogorov–Smirnov test. Comparisons between groups were performed using the Mann–Whitney U test for continuous variables and Pearson's chi‐square or Fisher's exact test for categorical variables. A p‐value < 0.05 was considered statistically significant. Statistical analyses were conducted using IBM SPSS Statistics for Windows, Version 25.0 (Armonk, NY: IBM Corp). A Cox proportional hazards model for time‐to‐event outcomes was not performed because of the very limited number of outcome events (death). For several variables, no events were observed, which would compromise model stability, lead to convergence problems, and limit interpretability of the results. Ethical Considerations This study was approved by the Institutional Ethics Committee of Dr. Balmis General University Hospital – ISABIAL (EXP. PI2024‐160). The requirement for informed consent was waived due to the retrospective nature of the study. The research was conducted in accordance with the principles outlined in the Declaration of Helsinki. Results Patient Demographics A total of 32 patients diagnosed with PG were evaluated during the study period, with a median incidence of 1.3 cases per year. The majority were women (24 patients, 75%), compared to 8 men (25%). The overall mean age at diagnosis was 57 years (range: 15–91). Among male patients, the mean age at onset was 44 years (IQR: 30–49; range: 13–91). Obesity was present in 44.4% of patients, while 6.2% reported alcohol or drug use (Table 1). Table 1Summary of characteristic of 32 cases of pyoderma gangrenosum.TotalSex, % (n/N)Men25.0 (8/32)Women75.0 (24/32)Age (Year), median (IQR)41 (30‐59)Comorbidities, % (n/N)Obesity44.4 (8/18)Drugs consumption6.2 (2/32)Alcohol consumption6.2 (2/32)Tabaco consumption, no53.1 (17/32)Tabaco consumption, yes28.1 (9/32)Tabaco consumption, Ex18.8 (6/32)Pyoderma gangrenous, % (n/N)Type of PGUlcerative PG46.9/15/32)Pustular PG25.0 (8/32)Bullous PG21.9 (7/32)Vegetative PG6.3 (2/32)Days until diagnosis, median (IQR)36 (5‐53)Number of lesions, median (IQR)1 (1‐2)Location of lesion, % (n/N)Lower extremities86.4 (27/32)Trunk29.2 (9/32)Upper extremities6.2 (2/32)Head3.1 (1/31)Genital3.1 (1/32)Underlying conditions, % (n/N)Bowel inflammatory disease21.8 (7/32)Ulcerative colitis12.5 (4/32)Chron diseases9.4 (3/32)Rheumatoid arthritis15.6 (5/32)Seronegative arthritis9.4 (3/32)Spondylitis6.3 (2/32)Gammopathy3.2 (1/32)Myeloproliferative syndrome3.1 (1/32)Sweet's syndrome3.1 (1/32)Osteotomy surgical3.1 (1/32)Non underlying condition6.7 (21/32)Analytical results, median (IQR)Hemoglobin, g/dl (n = 22)11.7 (9.1–12.2)Leukocytes x103 (n = 22),8.3 (7.1–12.3)Glucose, mg/dL (n = 23)88 (77–98)Creatinine, mg/dL (n = 22)0.77 (0.57–1.06)Total cholesterol, mg/dL (n = 17)160 (113–185)Aspartate amino transferase, mg/dL (n = 21)16 (12–29)C‐reactive protein mg/dl (n = 19)3.5 (0.8–7.2)Treatment of control, % (n/N)Systemic77.4 (24/31)Topic48.4 (15/31)Biological22.6 (7/31)Surgery15.6 (15.6)Follow upMonths until remission of PG, median (IQR)19 (16–29)Death during follow the patients9.4 (3/32)Abbreviations: % (n/N) percentages (number of events/sample size). Summary of characteristic of 32 cases of pyoderma gangrenosum. Abbreviations: % (n/N) percentages (number of events/sample size). Clinical Presentation and Associated Conditions A detailed description of all PG cases is provided in Table 2. The most frequent clinical subtype was ulcerative PG (46.9%, n = 15), followed by pustular (25.0%, n = 8), bullous (21.9%, n = 7), and vegetative PG (6.3%, n = 2). The median number of lesions was 1 (IQR: 1–2). The most affected site was the lower extremities (86.4%, n = 27), followed by the trunk (25.9%, n = 9). Table 2Clinical characteristics of 32 of cases of pyoderma gangrenosum.Year of diagnosisSexAgeDays until diagnosisUnderlying diseasesMonths until remissionFinal treatment* RemarksTopicalSystemicBiological2000W300Ulcerative colitis16 Corticosteroids antibiotics Cyclosporin2001W48500141 Corticosteroids Cyclosporin Infliximab2002W4300NA Corticosteroids Cyclosporin 2005M4456019 Corticosteroids Cyclosporin 2006W360Rheumatoid arthritis12 Corticosteroids Cyclosporin 2007W3190Rheumatoid arthritis47 Corticosteroids antibiotics Tacrolimus CorticosteroidsLupus + APS2007M5539Seronegative arthritis8 Corticosteroids antibiotics Corticosteroids2008M6238Rheumatoid arthritis19 Corticosteroids antibiotics Corticosteroids2008W8142Rheumatoid arthritis29 Corticosteroids cyclosporin 2008W38222Rheumatoid arthritis25 Corticosteroids antibiotics Corticosteroids2009M7944Monoclonal gammopathy16Corticosteroids2009W13530142 Corticosteroids antibiotics tacrolimus Antibiotics cyclosporin 2009M6060015 Corticosteroids tacrolimus 2010W2012021 Corticosteroids Antibiotics 2011W8733019CorticosteroidsEtanercept2011W235Ulcerative colitis98Infliximab2012W39460108CyclosporinCanakinumab2012W5520 Crohn's disease Seronegative arthritis IBD spondylitis 19Tacrolimus Corticosteroids Cyclosporin Adalimumabb 2012W525Ulcerative colitis17 Corticosteroids Cyclosporin 2013W427Ulcerative colitis23 Corticosteroids antibiotics Infliximabb 2014W3442Crohn's disease16AntibioticsCyclosporin2014W402014 Corticosteroids Cyclosporin 2015W192020Tacrolimus Corticosteroids Cyclosporin 2016W3030018Antibiotics2016W4030096Corticosteroids2017W292 Crohn's disease IBD spondylitis 13 Corticosteroids antibiotics CorticosteroidsInfliximaba 2017W5517030Corticosteroids2019M923702Death not related: Severe aortic stenosis2019W23155Sweet's syndrome17AntibioticsCorticosteroids2020W38339020 Corticosteroids Cyclosporin 2020M73135030 Corticosteroids Cyclosporin Death no related End‐stage kidney disease2022M6136 Seronegative arthritis Myelodysplastic syndrome 12Death not related: intracranial hemorrhageAbbreviations: APS, antiphospholipid antibody syndrome; M, male; NA, not available; W, female.*Final treatment to control of disease. a Anti‐TNF treatment administered before PG diagnosis. b Anti‐TNF treatment initiated after PG diagnosis. Clinical characteristics of 32 of cases of pyoderma gangrenosum. Corticosteroids antibiotics Corticosteroids Cyclosporin Corticosteroids Cyclosporin Corticosteroids Cyclosporin Corticosteroids Cyclosporin Corticosteroids antibiotics Tacrolimus Corticosteroids antibiotics Corticosteroids antibiotics Corticosteroids cyclosporin Corticosteroids antibiotics Corticosteroids antibiotics tacrolimus Antibiotics cyclosporin Corticosteroids tacrolimus Corticosteroids Antibiotics Crohn's disease Seronegative arthritis IBD spondylitis Corticosteroids Cyclosporin Corticosteroids Cyclosporin Corticosteroids antibiotics Corticosteroids Cyclosporin Corticosteroids Cyclosporin Crohn's disease IBD spondylitis Corticosteroids antibiotics Corticosteroids Cyclosporin Corticosteroids Cyclosporin Seronegative arthritis Myelodysplastic syndrome Abbreviations: APS, antiphospholipid antibody syndrome; M, male; NA, not available; W, female. Final treatment to control of disease. Anti‐TNF treatment administered before PG diagnosis. Anti‐TNF treatment initiated after PG diagnosis. Regarding associated systemic conditions, 21.8% (n = 7) had inflammatory bowel disease, 15.6% (n = 5) had rheumatoid arthritis, and 9.4% (n = 3) had seronegative spondyloarthritis. No case of paraneoplastic PG or hematologic malignancies were identified. Key laboratory findings at diagnosis are summarized in Table 1. Notably, the median hemoglobin level was below 12.0 g/dL, suggesting anemia. Treatment and Follow‐Up The median time to clinical remission was 19 months (IQR: 16–29). Treatment strategies included systemic therapy (77.4%), topical therapy (48.4%), biologic therapy (22.6%), and surgery (15.6%). Specific treatment details are presented in Table 3. During the follow‐up period, 9.4% of the patients died. Table 3Initial and Final Treatment of 32 cases of pyoderma gangrenosuma.Initial treatment % (n)Final treatment % (n)Topic treatment 56.3 (18) 46.9 (15) Corticoids40.6 (13)34.4 (11)Antibiotics43.8 (14)37.5 (12)Tacrolimus6.3 (2)15.6 (5)Systemic treatment 87.5 (28) 78.1 (25) Corticoids71.9 (23)65.6 (21)Cyclosporine31.25 (10)46.9 (15)Azathioprine3.1 (1)0 (0)Antibiotics25 (8)3.1 (1)Biological treatment 9.4 (3) 21.9 (7) Infliximab6.3 (2)12.5 (4)Rituximab3.1 (1)0 (0)Etanercept(0)3.1 (1)Canakinumab(0)3.1 (1)Adalimumab(0)3.1 (1)Surgery 15.6 (5) Skin grafts12.5 (4)Dermal matrix6.3 (2) a The total number of treatments exceeds 32 because some patients received more than one type of therapy. Initial and Final Treatment of 32 cases of pyoderma gangrenosuma. The total number of treatments exceeds 32 because some patients received more than one type of therapy. Sex‐Based Differences Table 4 presents the comparison of epidemiological, clinical, therapeutic, and prognostic features between sexes. Male patients were significantly older than female patients (median age: 61 vs. 41 years; p < 0.001) and had a longer interval from symptom onset to diagnosis (41.5 vs. 20 days; p = 0.05). No significant differences were found in the PG subtype, lesion location, or associated conditions. However, some laboratory parameters differed between sexes: men had lower median levels of glucose, creatinine, and hemoglobin than women. Mortality during follow‐up was significantly higher in men (37.5%) compared to women (0.0%) (p = 0.01). Table 4Differences of clinical characteristic of pyoderma gangrenosum by sex.MenWomen p valuea Age (Year), median (IQR)61 (58–76)38 (29–45) < 0.001 Comorbidities, % (n/N)Obesity40.0 (2/5)46.3 (6/13)> 0.99Drugs consumption0.0 (0/8)4.8 (2/24)> 0.99Alcohol consumption12.5 (1/8)4.2 (1/24)0.44Tabaco consumption62.5 (5/8)41.7 (10/24)0.42Pyoderma gangrenous% (n/N)Type of PGUlcerative PG50.0 (4/4)45.8 (11/18)0.92Pustular PG25.0 (2/4)25.0 (6/24)> 0.99Bullous PG12.5 (1/8)25.0 (6/24)0.57Vegetative PG12.5 (1/8)4.2 (1/24)0.75Days until diagnosis, median (IQR)41.5 (37.5–58)20 (3.5–44) 0.05 Number of lesions, median (IQR)2 (1‐2)1 (1‐2)0.43Location of lesion, % (n/N)Lower extremities75.0 (6/8)87.5 (21/24)0.78Trunk3.75 (3/8)25.0 (6/24)0,65Upper extremities12.5 (1/8)4.2 (1/24)> 0.99Head0.0 (0/8)4.2 (1/24)> 0.99Genital0.0 (0/8)14.2 (1/24)> 0.99Underlying conditions, % (n/N)Bowel inflammatory disease0.0 (0/8)29.1(7/24)0.15Ulcerative colitis0.0 (0/8)16.7 (4/24)0.55Chron diseases0.0 (0/8)12.5 (3/24)0.55Rheumatoid arthritis12.5 (1/8)16.7 (4/24)> 0.99Seronegative arthritis25.0 (2/8)4.2 (1/24)0.15Spondylitis0.0 (0/8)8.3 (2/24)> 0.99Gammopathy12.5 (1/8)0.0 (0/24)> 0.99Myelodysplastic syndrome12.5 (1/8)0.0 (0/24)> 0.99Sweet's syndrome0.0 (0/8)4.2 (1/24)> 0.99Osteotomy surgical0.0 (0/8)4.2 (1/24)> 0.99Non underlying condition37.5 (3/8)45.8 (11/24)> 0.99Analytical results, median (IQR)Hemoglobin, g/dL (n = 22)9.6 (9.2–12.5)12.6 (9.3–13.3) 0.002 Leukocytes x103/l (n = 22)8.6 (6.0–16.5)8.2 (7.1–11.5)0.91Glucose, mg/dL (n = 23)104 (96–113)81 (76–91) 0.006 Creatinine, mg/dL (n = 22)1.25 (1.06–1.14)0.68 (0.51–0.79) 0.001 Total cholesterol, mg/dL (n = 17)81.5 (76–87)164 (138–185) 0.02 Aspartate amino transferase, mg/dL (n = 21)30 (30‐30)15 (11–17)C‐reactive protein mg/dL (n = 19)3.5 (1.1–7.3)3.5 (0.8–5.3)0.52Treatment of control, % (n/N)Topic42.9 (3/7)50.0 (12/24)1.00Systemic71.5 (71.4)79.2 (19/24)0.64Biological0.0 (0/7)29.2 (7/2490.16Surgery12.5 (1/8)4 (16.7)1.00Follow upMonths until remission of PG, median (IQR)16 (15–19)20 (17–30) 0.04 Death during follow the patients37.5 (3/8)0.0 (0/24) 0.01 Note: % (n/N) percentages (number of events/sample size). a The statistical test used was the chi‐square test for categorical variables and the U Mann Whiteny Test for continuous variables. In bond p value < 0.05. Differences of clinical characteristic of pyoderma gangrenosum by sex. Note: % (n/N) percentages (number of events/sample size). The statistical test used was the chi‐square test for categorical variables and the U Mann Whiteny Test for continuous variables. In bond p value < 0.05. Mortality and Risk Factors Over the Study Period Among the 32 patients, 3 died from other cause nonrelated with PG during follow‐up (Table 2), yielding a mortality prevalence of 9.4% (95% CI: 3.2%–24.2%). Univariate analysis of factors associated with mortality is shown in Table 5. Significant associations were found for age (median: 73 vs. 40 years; p = 0.03), and sex (mortality in 37.5% of men vs. 0.0% of women; p = 0.01). Mortality was not significantly associated with comorbid conditions or treatment modalities. Table 5Risk factors for mortality in pyoderma gangrenosum patients.Mortality % (n/N)a OR (95% CI) p valueb Age (Year), median (IQR)Survived40.0 (30–55)1—Non survived73 (67–82)1.09 (1.01–1.19) 0.03 SexMen37.5 (3/8)1 0.01 Women0.0 (0/24)NA—TabacoNo11.8 (2/17)1Yes6.7 (1/15)0.53 (0.4–6.58)> 0.99Type of PGUlcerative PGNo0.0 (0/17)1Yes20.0 (3/15)NA c 0.09Pustular PGNo12.5 (3/24)1Yes0.0 (0/8)NA c > 0.99Bullous PGNo12.0 (3/25)1Yes0.0 (0/7)NA c 0.55Vegetative PGNo10.0 (3/30)1Yes0.0 (0/2)NA c > 0.99Days until diagnosis, median (IQR)Survived37.0 (36.5–86)1Non survived31.5 (5–49.5)1.00 (0.99–1.02)0.65Number of lesions, median (IQR)Survived1 (1–2)1Non survived1 (1–1.5)0.47 (0.07–2.92)0.42Main location of lesionLower extremitiesNo40 (2/5)17.33 (1.19‐253)0.06Yes3.7 (1/27)1TrunkNo4.3 (1/23)1Yes22.2 (2/9)6.28 (0.49‐80)0.18Underlying conditionNo16.7 (3/18)1Yes0.0 (0/14)NA c 0.51TreatmentTopicNo14.3 (2/14)1Yes5.6 (1/18)0.75 (0.92‐6.11)> 0.99SystemicNo0.0 (0/4)1Yes10.7 (3/28)NA c > 0.99BiologicalNo10.3 (3/29)1Yes0.0 (0/3)NA c > 0.99 a The results are presented as percentage (%); number of cases (n), total number (N) in categorical variables and median with interquartile range (IQR) in continuous variables. b The statistical test used was the chi‐square test for categorical variables and the U Mann Whiteny Test for continuous variables. In bond p value < 0.05. c The Odds ratio (OR) is no available (NA) because one category the value is zero. Risk factors for mortality in pyoderma gangrenosum patients. The results are presented as percentage (%); number of cases (n), total number (N) in categorical variables and median with interquartile range (IQR) in continuous variables. The statistical test used was the chi‐square test for categorical variables and the U Mann Whiteny Test for continuous variables. In bond p value < 0.05. The Odds ratio (OR) is no available (NA) because one category the value is zero. Discussion Our retrospective case series of 32 patients with PG offers valuable insights into the demographics, clinical presentations, treatment responses, and associated comorbidities of this complex dermatologic condition. The findings are consistent with previously published data [3, 4, 5, 6, 8, 9, 10]. PG predominantly affected adults, with a median age of 41 years, and was more common in women, with a female‐to‐male ratio of 4:1, aligning with the literature. This sex disparity, as also noted in prior studies, raises intriguing questions about potential hormonal, genetic, or immunological factors predisposing women to PG. In our study the most frequent clinical subtype was ulcerative PG pustular, bullous and vegetative. The proportion of bullous PG (21.9%) was higher than reported in the literature (generally < 7% of cases) [22]. Bullous PG is often linked to hematologic malignancies—particularly myeloproliferative disorders—and is associated with higher mortality [23, 24, 25]. In our series, however, none of these patients had a myeloproliferative disorder and no deaths were observed. This discrepancy may reflect differences in patient selection, referral patterns, or underlying comorbidities [22, 26]. Besides, our findings reinforce the strong association between PG and inflammatory bowel diseases (IBD), observed in 21.2% of our patients—comparable to the 20%–30% range reported in the literature [4, 5, 6, 9, 10]. Several large case series have examined PG in the context of IBD [6, 11, 12]. Notably, the prevalence of rheumatoid arthritis, seronegative arthritis, and spondylitis (31.3%) in our cohort was higher than in other reports [8, 9, 17, 18]. Specific studies have analyzed the association between PG and rheumatologic conditions [13, 19], highlighting the systemic nature of PG and its overlap with other inflammatory disorders [3, 4, 9, 17, 18]. Hematologic malignancies such as lymphoma, monoclonal gammopathies and myelodysplastic syndrome were infrequent associate with PG [3, 4, 9, 17, 18]. No case of paraneoplastic PG or hematologic malignancies were identified in our series. Possible explanations for this finding, include case selection and referral bias, as well as the inherent diagnostic challenges in distinguishing paraneoplastic PG from other ulcerative dermatoses. The retrospective design and relatively small sample size of our series may also have contributed to this absence. Previous studies have highlighted the variable frequency of paraneoplastic PG and the difficulty of establishing a causal relationship with hematologic malignancies [22, 26], which could further explain the underrepresentation observed in our cohort. We did not observe other conditions previously associated with PG, hidradenitis suppurativa, or Behçet's disease [20]. Additionally, we did not encounter rare autoinflammatory syndromes like PAPA (pyogenic arthritis, PG, and acne), PASH (PG, acne, and hidradenitis suppurativa), or PAPASH (pyogenic arthritis, acne, PG, and hidradenitis suppurativa) [2, 3, 4, 5, 6, 9], which may be due to the single‐center nature of our study. However, we did report one case of Sweet's syndrome, another inflammatory condition associated with PG [26]. Obesity emerged as a relevant factor in our analysis. Half of the patients with available BMI data were classified as obese, in line with other case series [4, 5, 9]. This is particularly relevant given that obesity is associated with a reduced therapeutic response in inflammatory dermatoses like psoriasis, potentially due to a chronic pro‐inflammatory state driven by elevated cytokine levels [9]. Lower extremity involvement was the most common anatomical presentation, consistent with prior studies [3, 4, 6, 8, 9, 10, 27, 28]. This distribution may suggest contributing factors such as trauma, vascular insufficiency, or localized immune dysregulation—areas that warrant further investigation [27, 28]. The treatment of PG includes a variety of approaches [29]. Initial management typically involves topical therapies (e.g., corticosteroids or tacrolimus), followed by or combined with systemic treatments such as corticosteroids, cyclosporine, or azathioprine. Antibiotics may be added if secondary infection is suspected. More recently, biologic therapies have been incorporated, offering improved control of both cutaneous symptoms and underlying systemic disease—as seen with infliximab [30]. In selected cases, surgical interventions are employed to achieve disease control [29]. This therapeutic landscape is reflected in our study. Variations in treatment across published case series likely reflect the availability of medications over time, emerging evidence, and institutional practices [3, 4, 6, 8, 9, 10]. Paradoxical cases of PG related to anti‐TNF agents such as infliximab have been described in the literature. In our series, only one patient with IBD was already receiving infliximab at the time of PG onset. PG improved after the addition of systemic corticosteroids without discontinuation of the biologic therapy. The retrospective design of our study and the incomplete clinical information available did not allow us to establish whether this case represented a true paradoxical reaction or a coincidental association [31]. These limitations highlight the need for prospective studies with systematic data collection to better clarify the relationship between biologic therapies, underlying immune‐mediated conditions, and the development of PG. Large population‐based studies have shown increased all‐cause and cause‐specific mortality in patients with PG compared to the general population, including cohorts from Korea [32] and Denmark [33]. In our study, 1 in 10 patients died during follow‐up—higher than the 5% reported in other series [20]. Due to limitations in data, we could not determine whether mortality was directly related to PG. The age and sex (male) were the only variable associated with mortality, consistent with findings from a retrospective study using Spain's national hospital discharge registry [20]. Shakshouk et al. [15] reported infections, pulmonary embolism, and myelodysplastic syndrome as leading causes of death in PG patients at autopsy, suggesting a need to explore the relationship between PG and thrombosis. This may be linked to underlying malignancies or a prothrombotic state driven by chronic inflammation. We also observed that male patients were older, had delayed diagnoses, lower hemoglobin levels, and experienced higher mortality. These trends may reflect a more severe disease course in older individuals. No significant sex differences were found in PG subtype, lesion location, associated comorbidities, or treatment. Although the sample size limits generalizability, these findings support the need for heightened vigilance in diagnosing and managing PG in male patients. The strengths of our study include its single‐center design and consistent follow‐up, allowing for homogeneous data collection. However, limitations include its retrospective nature, with incomplete data for some variables. Additionally, cases managed by other specialists may not have been fully captured, limiting insight into the multidisciplinary approach critical in PG care. Management of PG often requires collaboration among dermatologists, rheumatologists, gastroenterologists, and surgeons [9]. We also did not assess the interval between the onset of comorbidities and PG diagnosis. Other limitation was the small sample size (32 patients) and the very low number of deaths (n = 3) precluded the use of Cox proportional hazards models to analyze time‐to‐event outcomes. In this context, performing such analyses would have produced unstable estimates with wide confidence intervals and limited clinical interpretability. Therefore, we restricted our analyses to descriptive and univariate approaches. In summary, our study contributes to the understanding of PG by reaffirming its association with systemic diseases and highlighting diagnostic and management challenges. Despite limitations, it represents one of the largest single‐center case series in Spain, emphasizing the predominance of PG in women with IBD and arthritis, and noting important sex differences in disease presentation and outcomes. Further prospective studies are essential to elucidate PG pathogenesis, optimize treatment, and improve patient outcomes in this difficult‐to‐manage condition. Author Contributions José‐Manuel Ramos‐Rincón: conceptualization, analysis, investigation, writing – original draft, writing – review and editing. Jorge Esteban‐Jarabo: data curation, formal analysis, investigation, writing – review and editing. Marina Senent: data curation, formal analysis, writing – review and editing. Isabel Belinchón‐Romero: conceptualization, investigation, writing – original draft, writing – review and editing. Disclosure The lead author José‐Manuel Ramos‐Rincón, Isabel Belinchón‐Romero affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments We would like to acknowledge the staff of Dermatology Dr. Balmis General University Hospital for caring the patients during 25 years of the study. This work was supported by Alicante Health and Biomedical Research Institute under Grant 2025‐0181 to I.B.R. All authors have read and approved the final version of the manuscript. The corresponding authors had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis. Ramos‐Rincón J.‐M., Esteban‐Jarabo J., Senent M., and Belinchón‐Romero I., “Pyoderma Gangrenosum in Spain: Clinical Features, Therapeutic Management, and Outcomes in a 32‐Patient Case Series,” Health Science Reports 8 (2025): 1‐11, 10.1002/hsr2.71537. Contributor Information José‐Manuel Ramos‐Rincón, Email: jose.ramosr@umh.es. Isabel Belinchón‐Romero, Email: ibelinchon@umh.es. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.